肝炎診断検査市場レポート：検査タイプ別、地域別、2025年～2033年

肝炎診断検査市場の世界市場規模は2024年に61億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに90億米ドルに達し、2025～2033年の成長率（CAGR）は4.23％になると予測しています。同市場は、世界中で肝炎の有病率が上昇していること、診断法における急速な技術進歩、一般市民の意識向上とスクリーニングの取り組み、政府による支援政策と資金提供の実施、医療保険の適用範囲と償還政策の拡大などにより、力強い成長を遂げています。

肝炎診断検査市場分析：

市場の成長と規模世界の肝炎罹患率の上昇、診断技術の急速な進歩、医療保険の適用範囲と償還政策の拡大などを背景に、市場は安定した成長を遂げています。

主な市場促進要因：市場成長に影響を与える主な促進要因としては、肝炎の罹患率の増加、検査法の急速な進歩、肝炎の予防と治療に関する世界の意識の高まり、政府のイニシアティブと資金援助の賦課などが挙げられます。

主要市場動向：主な市場動向には、技術革新による非侵襲的で迅速な検査法へのシフトがあります。さらに、肝炎の早期発見と管理を強化するために、ポイントオブケア検査（POCT）と個別化医療への注目が高まっていることも、市場の成長を後押ししています。

地理的動向：北米は高度なヘルスケアシステムと高い認知度により市場をリードしています。その他の地域も、ヘルスケアインフラの整備や政府による支援策の実施に後押しされ、大きな伸びを示しています。

競合情勢：市場は、先進的な診断薬を導入するための研究開発（R&D）に注力する主要企業の積極的な関与によって特徴付けられています。さらに、各社は市場でのプレゼンスを拡大し、製品ポートフォリオを強化するために、戦略的提携、合併、買収に取り組んでいます。

課題と機会：市場は、特に低開発地域におけるヘルスケアアクセスの格差や、費用対効果の高い検査ソリューションの必要性など、さまざまな課題に直面しています。しかし、技術革新の高まりや新興国市場へのヘルスケアサービスの拡大は、市場成長の新たな機会を生み出しています。

肝炎診断検査市場動向：

世界の肝炎有病率の増加

B型肝炎やC型肝炎などの肝炎有病率の増加は、市場成長を後押しする主要因の1つです。さらに、早期肝炎の無症状性についての認識の高まりが、診断検査の必要性を高め、市場成長の触媒となっています。これに加えて、輸血、安全でない注射、出産時の母子感染などによるトランスミッションの急増が、市場成長に拍車をかけています。これとともに、肝炎患者の早期診断と定期的なモニタリングの必要性が高まっていることも、肝炎を管理し、肝硬変や肝細胞がんなどの重篤な段階への進行を防ぐために、市場成長を促進しています。これに伴い、ウイルスの存在を検出し、肝機能を評価し、治療効果をモニターする必要性から、診断検査に対する需要が増加しており、市場の成長を促進しています。

診断技術の急速な進歩

検査手法の急速な技術進歩と革新は、より正確で効率的、かつ侵襲性の低い検査の開発につながり、市場の成長を促進しています。さらに、次世代シーケンシング（NGS）、リアルタイムポリメラーゼ連鎖反応（PCR）、迅速診断検査（RDT）など、より高い感度と特異度でより迅速な結果を提供する最新の診断ツールの開発は、成長を促進する要因として作用しています。これらは肝炎診断の精度を高め、結果を得るのに必要な時間を短縮します。これに加えて、ポイント・オブ・ケア検査（POCT）の急速な進歩により、従来の検査室以外でも肝炎検査を実施できるようになったことが、市場の成長を後押ししています。このほか、医療従事者や患者の進化するニーズに対応するため、官民からの多額の投資に支えられた診断技術の研究開発が進められていることも、市場の成長を後押ししています。

疾患に対する意識の高まりと教育キャンペーン

肝炎とその影響に関する認識が高まり、スクリーニングや検査が広く行われるようになったことは、市場成長を後押しする主な要因の1つです。これに伴い、肝炎に関連するリスクと早期診断・治療の重要性について一般市民を教育するために、様々な政府保健機関、非営利団体（NGO）、ヘルスケアプロバイダーが注力していることが、市場成長を後押ししています。これとともに、自発的な検査を受けるよう促すいくつかの啓発キャンペーンのイントロダクションが、市場の成長を刺激しています。さらに、安全でない注射行為、スクリーニングされていない輸血、無防備な性的接触など、この病気に対する一般的な理解を深めるための取り組みの高まりが、市場の成長に寄与しています。

さまざまな政府イニシアチブの実施

肝炎診断サービスの普及と効率性を高めるための様々な政府イニシアチブの実施は、市場成長を強化する主な要因です。さらに、研究、診断施設の市場開拓、国家肝炎対策プログラムへの支援のための投資が増加していることも、市場の成長を後押ししています。これに加えて、肝炎の予防、診断、治療のための戦略を開発・実施し、さまざまなヘルスケア環境において質の高い検査を保証するための国際機関との協力関係の高まりが、市場の成長を大きく後押ししています。さらに、政府の資金援助により診断検査費用が補助され、より多くの人々が検査にアクセスしやすくなっています。

医療保険の適用範囲拡大と償還政策

健康保険の適用範囲拡大と有利な償還政策の開発は、市場成長を促進する要因です。さらに、肝炎が公衆衛生上の問題であるとの認識が高まり、医療保険プロバイダーが肝炎診断検査を保険サービスの一部に含めるようになったことも、市場成長を加速させています。これに加えて、肝炎検査をカバーする政府出資の保険制度がイントロダクションとして導入され、早期診断を求めるよう個人を奨励していることも、市場成長の起爆剤となっています。さらに、医療提供者が患者に検査を勧めることを容易にする償還政策への注目の高まりが、市場成長を促進すると予想されます。保険償還は、検査機関や診断センターがより幅広い肝炎検査を提供するインセンティブとなり、高度な検査オプションの利用可能性を高める。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の肝炎診断検査市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場内訳：検査タイプ別
• 市場内訳：地域別
• 市場予測
• SWOT分析
  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威
• バリューチェーン分析
• ポーターのファイブフォース分析
  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威
• 価格分析

第6章 市場内訳：検査タイプ別

• 血液検査
  • 市場動向
  • 市場予測
• 画像検査
  • 市場動向
  • 市場予測
• 肝生検
  • 市場動向
  • 市場予測

第7章 市場内訳：地域別

• アジア太平洋地域
• 北米
• 欧州
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Siemens AG
  • Abbott Laboratories
  • MedMira Inc
  • Qiagen GmbH
  • Beckman Coulter Inc（Danaher Corporation）
  • F. Hoffmann-La Roche AG
  • Diasorin S.p.A
  • bioMeriuex SA
  • Hologic Inc
  • Bio-Rad Laboratories Inc

List of Figures

• Figure 1: Global: Hepatitis Diagnostic Tests Market: Major Drivers and Challenges
• Figure 2: Global: Hepatitis Diagnostic Tests Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Hepatitis Diagnostic Tests Market: Breakup by Test Type (in %), 2024
• Figure 4: Global: Hepatitis Diagnostic Tests Market: Breakup by Region (in %), 2024
• Figure 5: Global: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 6: Global: Hepatitis Diagnostic Tests Industry: SWOT Analysis
• Figure 7: Global: Hepatitis Diagnostic Tests Industry: Value Chain Analysis
• Figure 8: Global: Hepatitis Diagnostic Tests Industry: Porter's Five Forces Analysis
• Figure 9: Global: Hepatitis Diagnostic Tests (Blood Test) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Hepatitis Diagnostic Tests (Blood Tests) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Hepatitis Diagnostic Tests (Imaging Test) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Hepatitis Diagnostic Tests (Imaging Test) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: North America: Hepatitis Diagnostic Tests Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: North America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Asia Pacific: Hepatitis Diagnostic Tests Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Asia Pacific: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Europe: Hepatitis Diagnostic Tests Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Europe: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Middle East and Africa: Hepatitis Diagnostic Tests Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Middle East and Africa: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Latin America: Hepatitis Diagnostic Tests Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Latin America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

• Table 1: Global: Hepatitis Diagnostic Tests Market: Key Industry Highlights, 2024 & 2033
• Table 2: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Test Type (in Million USD), 2025-2033
• Table 3: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 4: Global: Hepatitis Diagnostic Tests Market: Competitive Structure
• Table 5: Global: Hepatitis Diagnostic Tests Market: Key Players

The global hepatitis diagnostic tests market size reached USD 6.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.23% during 2025-2033. The market is experiencing robust growth, driven by the rising prevalence of hepatitis across the globe, rapid technological advancements in diagnostics, increasing public awareness and screening initiatives, implementation of supportive government policies and funding, and the expansion of health insurance coverage and reimbursement policies.

Hepatitis Diagnostic Tests Market Analysis:

Market Growth and Size: The market is witnessing stable growth, driven by the rising prevalence of hepatitis across the globe, rapid advancements in diagnostic technologies, and the expansion of health insurance coverage and reimbursement policies.

Major Market Drivers: Key drivers influencing the market growth include the growing incidence of hepatitis, rapid advancements in testing methods, rising awareness about hepatitis prevention and treatment across the globe, and the imposition of government initiatives and funding.

Key Market Trends: The key market trends involve the ongoing shift towards non-invasive and rapid testing methods, driven by technological innovation. Additionally, the increasing focus on point-of-care testing (POCT) and personalized medicine to enhance early detection and management of hepatitis, is bolstering the market growth.

Geographical Trends: North America leads the market due to its advanced healthcare system and high awareness levels. Other regions are also showing significant growth, fueled by rising healthcare infrastructure and implementation of supportive government initiatives.

Competitive Landscape: The market is characterized by the active involvement of key players who are focusing on research and development (R&D) to introduce advanced diagnostics. Furthermore, companies are engaging in strategic partnerships, mergers, and acquisitions to expand their market presence and enhance product portfolios.

Challenges and Opportunities: The market faces various challenges, such as disparities in healthcare access, particularly in underdeveloped regions, and the need for cost-effective testing solutions. However, the rising innovation, and expansion of healthcare services into emerging markets are creating new opportunities for the market growth.

Hepatitis Diagnostic Tests Market Trends:

Increasing prevalence of hepatitis across the globe

The increasing prevalence of hepatitis, such as hepatitis B and C, is one of the major factors propelling the market growth. Moreover, the growing awareness about the asymptomatic nature of early-stage hepatitis, boosting the need for diagnostic tests, is catalyzing the market growth. Besides this, the burgeoning cases of transmission through blood transfusion, unsafe injection practices, and mother-to-child transmission during birth, are fueling the market growth. Along with this, the rising need for early diagnosis and regular monitoring of patients with hepatitis for managing the disease and preventing its progression to severe stages, such as liver cirrhosis and hepatocellular carcinoma, is catalyzing the market growth. In line with this, the increasing demand for diagnostic tests, driven by the necessity to detect the presence of the virus, assess liver function, and monitor the effectiveness of treatment, is enhancing the market growth.

Rapid advancements in diagnostic technologies

The rapid technological advancements and innovations in testing methodologies, leading to the development of more accurate, efficient, and less invasive tests, are fostering the market growth. Moreover, the development of modern diagnostic tools, such as next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and rapid diagnostic tests (RDTs) that offer faster results with higher sensitivity and specificity, are acting as a growth-inducing factor. They enhance the accuracy of hepatitis diagnosis and reduce the time required to obtain results. In addition to this, rapid advancements in point-of-care testing (POCT), making it possible to conduct hepatitis tests outside traditional laboratory settings, are fueling the market growth. Besides this, the ongoing research and development (R&D) in diagnostic technologies, supported by substantial investments from public and private sectors, to meet the evolving needs of healthcare providers and patients is driving the market growth.

Rising disease awareness and educational campaigns

The increasing awareness about hepatitis and its implications, leading to widespread screening and testing, is one of the major factors propelling the market growth. In line with this, the growing focus of various governmental health bodies, non-profit organizations (NGOs), and healthcare providers to educate the public about the risks associated with hepatitis and the importance of early diagnosis and treatment is bolstering the market growth. Along with this, the introduction of several awareness campaigns promoting individuals to undergo voluntary testing is stimulating the market growth. Furthermore, the rising efforts to increase the general understanding of the disease, such as unsafe injection practices, unscreened blood transfusions, and unprotected sexual contact, are contributing to the market growth.

Implementation of various government initiatives

The imposition of various government initiatives to enhance the reach and efficiency of hepatitis diagnostic services is a major factor strengthening the market growth. Moreover, the increasing investment in research, development of diagnostic facilities, and support for national hepatitis control programs, is fueling the market growth. In addition to this, the growing collaborations with international organizations to develop and implement strategies for hepatitis prevention, diagnosis, and treatment that ensure high-quality testing across various healthcare settings are providing a considerable boost to the market growth. Additionally, government funding aids in subsidizing the cost of diagnostic tests, making them more accessible to a broader section of the population.

Expansion of health insurance coverage and reimbursement policies

The expansion of health insurance coverage and the development of favorable reimbursement policies are key drivers favoring the market growth. Moreover, the increasing recognition of hepatitis as a public health issue, prompting health insurance providers to include hepatitis diagnostic tests as part of their covered services, is amplifying the market growth. Besides this, the introduction of government-funded insurance schemes that cover hepatitis testing while encouraging individuals to seek early diagnosis is catalyzing the market growth. Furthermore, the growing focus on your reimbursement policies, facilitating healthcare providers to recommend the tests to their patients, is anticipated to drive the market growth. Reimbursement incentivizes laboratories and diagnostic centers to offer a wider range of hepatitis tests, enhancing the availability of advanced testing options.

Hepatitis Diagnostic Tests Industry Segmentation:

Breakup by Test Type:

• Blood Tests
• Imaging Test
• Liver Biopsy

Blood tests accounts for the majority of the market share

Blood tests hold the largest market share due to their widespread availability, ease of use, and cost-effectiveness. They include enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and liver function tests to detect the presence of hepatitis viruses and assess liver damage. Moreover, the high sensitivity and specificity of the tests, making them the first line of diagnosis in most healthcare settings, is boosting the market growth. Additionally, rapid advancements in blood testing technologies, such as rapid diagnostic tests and point-of-care testing (POCT) devices, are anticipated to drive the market growth. Besides this, the increasing utilization of blood tests for large-scale screening programs, especially in areas with high prevalence rates, is bolstering the market growth.

Imaging tests include methods such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). They are utilized to assess the extent of liver damage in chronic hepatitis cases and to detect conditions like liver cirrhosis or liver cancer. Moreover, the growing importance of imaging tests in the staging of liver disease and guiding decisions regarding the need for more invasive procedures is favoring the market growth.

Liver biopsy involves the extraction of a small liver tissue sample for microscopic examination, providing detailed information about the extent of liver inflammation and fibrosis. They are employed in cases where blood and imaging tests are inconclusive or to assess the severity of liver damage more accurately. Moreover, liver biopsies offer critical insights in complex cases, influencing treatment decisions and management of chronic hepatitis patients.

Breakup by Region:

• North America
• Asia Pacific
• Europe
• Middle East and Africa
• Latin America

North America leads the market, accounting for the largest hepatitis diagnostic tests market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, the Middle East and Africa and Latin America. According to the report, North America accounted for the largest market share.

North America dominates the market due to its advanced healthcare infrastructure, high awareness levels about hepatitis, and substantial investment in healthcare. Moreover, the widespread adoption of cutting-edge diagnostic technologies, comprehensive screening programs, and robust government policies supporting hepatitis research and public health initiatives in the region are favoring the market growth. Along with this, the growing focus on early detection and prevention, driven by collaborations between healthcare providers, government agencies, and private organizations, is creating a positive outlook for the market growth. Besides this, the heightened research and development (R&D) activities, contributing to the introduction of innovative diagnostic solutions, are fueling the market growth.

The Asia Pacific region market is rapidly growing due to the high prevalence of hepatitis in the region, coupled with improving healthcare infrastructure, increasing public and private healthcare expenditure, and rising awareness about hepatitis and its implications. Moreover, the implementation of several government-funded large-scale screening and vaccination programs is bolstering the market growth.

Europe's hepatitis diagnostic tests market is growing, attributed to its well-established healthcare systems, high awareness of hepatitis, and strong government support for healthcare initiatives. Moreover, the widespread implementation of hepatitis screening and vaccination programs, is fueling the market growth. Besides this, the presence of leading healthcare companies and advanced research facilities in the region, contributing to the development and adoption of innovative diagnostic technologies, is fostering the market growth.

In Latin America, the hepatitis diagnostic tests market is growing, driven by the increasing prevalence of hepatitis. Moreover, the rising efforts to improve healthcare infrastructure and access to medical services are contributing to the market growth. Along with this, the growing focus by the governments and healthcare organizations in the region on awareness campaigns and improving diagnostic and treatment services for hepatitis is enhancing the market growth.

The market in the Middle East and Africa is evolving, with an increasing focus on addressing hepatitis. Moreover, the rising focus on enhancing healthcare services, with an emphasis on infectious disease control and prevention, is creating a positive outlook for the market. Additionally, the growing investment in healthcare and the adoption of modern diagnostic technologies are contributing to the market growth.

Leading Key Players in the Hepatitis Diagnostic Tests Industry:

The major players are engaged in a range of strategic activities to strengthen their market positions. They are investing in research and development (R&D) to introduce more advanced, accurate, and user-friendly diagnostic tests. Moreover, some companies are focusing on developing rapid and non-invasive testing methods that can provide quicker results with high accuracy. Besides this, they are involved in collaborations and partnerships with healthcare organizations, government bodies, and research institutions to enhance their product offerings and expand their geographical reach. Additionally, the leading firms are participating in awareness campaigns and educational programs to increase public knowledge about hepatitis and the importance of early diagnosis.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Siemens AG
• Abbott Laboratories
• MedMira Inc
• Qiagen GmbH
• Beckman Coulter Inc (Danaher Corporation)
• F. Hoffmann- La Roche AG
• Diasorin S.p.A
• bioMeriuex SA
• Hologic Inc.
• Bio-Rad Laboratories Inc.

Key Questions Answered in This Report

• 1.What was the size of the global hepatitis diagnostic tests market in 2024?
• 2.What is the expected growth rate of the global hepatitis diagnostic tests market during 2025-2033?
• 3.What are the key factors driving the global hepatitis diagnostic tests market?
• 4.What has been the impact of COVID-19 on the global hepatitis diagnostic tests market?
• 5.What is the breakup of the global hepatitis diagnostic tests market based on the test type?
• 6.What are the key regions in the global hepatitis diagnostic tests market?
• 7.Who are the key players/companies in the global hepatitis diagnostic tests market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hepatitis Diagnostic Tests Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Test Type
• 5.5 Market Breakup by Region
• 5.6 Market Forecast
• 5.7 SWOT Analysis
  • 5.7.1 Overview
  • 5.7.2 Strengths
  • 5.7.3 Weaknesses
  • 5.7.4 Opportunities
  • 5.7.5 Threats
• 5.8 Value Chain Analysis
• 5.9 Porters Five Forces Analysis
  • 5.9.1 Overview
  • 5.9.2 Bargaining Power of Buyers
  • 5.9.3 Bargaining Power of Suppliers
  • 5.9.4 Degree of Competition
  • 5.9.5 Threat of New Entrants
  • 5.9.6 Threat of Substitutes
• 5.10 Price Analysis

6 Market Breakup by Test Type

• 6.1 Blood Tests
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Imaging Test
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Liver Biopsy
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Region

• 7.1 North America
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Asia Pacific
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Europe
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Middle East and Africa
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Latin America
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Competitive Landscape

• 8.1 Market Structure
• 8.2 Key Players
• 8.3 Profiles of Key Players
  • 8.3.1 Siemens AG
  • 8.3.2 Abbott Laboratories
  • 8.3.3 MedMira Inc
  • 8.3.4 Qiagen GmbH
  • 8.3.5 Beckman Coulter Inc (Danaher Corporation)
  • 8.3.6 F. Hoffmann- La Roche AG
  • 8.3.7 Diasorin S.p.A
  • 8.3.8 bioMeriuex SA
  • 8.3.9 Hologic Inc
  • 8.3.10 Bio-Rad Laboratories Inc